Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry
Open Access
- 11 February 2021
- Vol. 76 (6) , 1813-1824
Abstract
Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic.Methods: A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician‐ and patient‐reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity.Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS‐CoV‐2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID‐related death occurred.Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab‐treated patients.Keywords
All Related Versions
This publication has 14 references indexed in Scilit:
- Optimizing care for atopic dermatitis patients during the COVID-19 pandemicJournal of the American Academy of Dermatology, 2020
- Safety of dupilumab in atopic patients during COVID-19 outbreakJournal of Dermatological Treatment, 2020
- No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, ItalyJournal of the European Academy of Dermatology and Venereology, 2020
- Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemicBritish Journal of Dermatology, 2020
- SARS‐CoV‐2 asymptomatic infection in a patient under treatment with dupilumabJournal of the European Academy of Dermatology and Venereology, 2020
- Safety of dupilumab in severe atopic dermatitis and infection of Covid‐19: two case reportsJournal of the European Academy of Dermatology and Venereology, 2020
- Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statementAllergy, 2020
- European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 2020
- Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic DermatitisJAMA Dermatology, 2020
- Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled AnalysisAmerican Journal of Clinical Dermatology, 2019